drugset / Trial / NCT03571438
Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
Timeline
- Start
- 2017-10-16
- Primary completion
- 2022-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ku 60019 | Small molecule | — | — |
| Comparator | Pazopanib | Small molecule | — | — |
| Subject | Silmitasertib | Small molecule | — | — |
| Comparator | Sunitinib | Small molecule | — | — |
| Comparator | Temsirolimus | Small molecule | — | — |